Multicenter Randomized Phase III Clinical Trial to Compare 6 FAC Cycles(Fluorouracil, Doxorubicin, Cyclophosphamide) vs. 4 FAC Cycles Followed by 8 Weekly Paclitaxel Administrations, as Adjuvant Treatment for Node Negative Operable Breast Cancer Patients.

Trial Profile

Multicenter Randomized Phase III Clinical Trial to Compare 6 FAC Cycles(Fluorouracil, Doxorubicin, Cyclophosphamide) vs. 4 FAC Cycles Followed by 8 Weekly Paclitaxel Administrations, as Adjuvant Treatment for Node Negative Operable Breast Cancer Patients.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Jun 2014

At a glance

  • Drugs Paclitaxel (Primary) ; Cyclophosphamide; Doxorubicin; Fluorouracil
  • Indications Early breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 May 2014 Biomarker results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
    • 03 Jun 2013 Primary endpoint 'Disease-free-survival-rate' has been met.
    • 03 Jun 2013 Results published in the Journal of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top